3 Beaten-Down Stocks With Rebound Potential This Earnings Season

Core Insights - Earnings season presents opportunities for lesser-known companies to gain attention, with three stocks highlighted for potential comebacks if their earnings reports are favorable [2] Company Overview - Scholar Rock Holding Corp. (NASDAQ: SRRK) is a biotech firm focused on developing protein therapeutics for neuromuscular diseases [3] - The lead asset, apitegromab, targets Type 2 and Type 3 Spinal Muscular Atrophy (SMA) and has shown promising Phase 3 data, indicating strong potential for regulatory approval in 2026 [4] Financial Performance - Scholar Rock's shares have declined approximately 33% year-to-date due to manufacturing site issues, raising short-term concerns [4] - The company is projected to report a loss per share of 76 cents for the third quarter, with no revenue expected yet [6] Clinical Development - A Phase 2 study of apitegromab demonstrated over 54% lean mass preservation compared to control when combined with GLP-1 agonist tirzepatide, indicating the drug's therapeutic promise [5] - Investors should look for updates on apitegromab and other drugs in the pipeline during the upcoming earnings report [6] Market Sentiment - Quarterly earnings reports can significantly impact share prices, with Scholar Rock, along with Globant and NiCE, being identified as companies that may see a rebound if they deliver strong earnings [7]